Developing and testing a new oral medication formulation.
SOCIETAL IS A SMALL BUSINESS CONCERN FOR DOSAGE FORM DEVELOPMENT, MANUFACTURE, AND STABILITY STUDIES OF NCGC72
['FUNDING_OTHER'] · IRISYS, INC. · NIH-10953952
This study is working on making a new tablet medication called NCGC72, which could help patients, by ensuring it's safe, effective, and stays good for a long time before it’s tested in people.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | IRISYS, INC. (nih funded) |
| Locations | 1 site (SAN DIEGO, UNITED STATES) |
| Trial ID | NIH-10953952 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a solid oral dosage form, specifically tablets, for a new drug called NCGC72. The process involves developing the formulation, validating the methods used to analyze the drug products, and manufacturing pilot batches. Additionally, the research includes ensuring that the drug product meets Good Manufacturing Practices (GMP) for a phase I clinical trial and conducting long-term stability studies to ensure the medication remains effective over time. Patients may benefit from this research as it aims to bring a new medication to market.
Who could benefit from this research
Good fit: Ideal candidates for participation would be individuals who may benefit from the new medication being developed, particularly those with conditions that the drug targets.
Not a fit: Patients who do not have the specific conditions targeted by the new medication may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of a new oral medication that may improve treatment options for patients.
How similar studies have performed: While this approach is common in drug development, the specific formulation and drug being tested may represent a novel application.
Where this research is happening
SAN DIEGO, UNITED STATES
- IRISYS, INC. — SAN DIEGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GIANNINI, ROBERT — IRISYS, INC.
- Study coordinator: GIANNINI, ROBERT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.